Mesoblast (ASX:MSB) shares rise as CEO reassures market on new FDA questions

Mesoblast’s CEO has reiterated the company is still working to gain FDA approval.
The post Mesoblast (ASX:MSB) shares rise as CEO reassures market on new FDA questions appeared first on The Motley Fool Australia. –

Holders of Mesoblast Limited (ASX: MSB) shares have responded positively to assurances from the company’s CEO that the US Food and Drug Administration (FDA) has not halted the development program of its key drug.

According to reporting by the Australian Financial Review (AFR), the Mesoblast share price has been sliding this week on news the FDA is upping its scrutiny of remestemcel-L.

In Mesoblast’s report for the financial year 2021, it stated the FDA has recently stipulated the company needs to provide potency assays before commencing a newly required additional clinical study. Only then, might the FDA approve remestemcel-L for emergency use to treat acute respiratory distress syndrome (ARDS) in COVID-19 sufferers.

The AFR quoted Mesoblast CEO, Silviu Itescu:

As Mesoblast has told the market, it is planning to meet with FDA in the coming quarter to present data on the potency assay for remestemcel-L in the treatment of children with acute GVHD.

The potency assays for remestemcel-L’s trial to treat pediatric steroid refractory acute graft versus host disease (SR-aGVHD) will likely be cross-referenced in the company’s submission for emergency use authorisation to treat ARDS in COVID-19 sufferers during the pandemic.

The Mesoblast share price fell 5.7% yesterday to finish the session trading at $1.57. It also dropped 15.3% on Tuesday after it released its FY21 earnings.

However, Mesoblast shares are gaining today. Right now, the Mesoblast share price is $1.61, 2.3% higher than yesterday’s close.

Let’s take a closer look at the assurances from the biotech company’s CEO.

Mesoblast shares gain as remestemcel-L still on FDA’s cards

The company announced results from a trial of remestemcel-L’s ability to treat ARDS in April. It found remestemcel-L reduced mortality in patients placed on ventilators after contracting COVID-19.

Following the positive result, the company decided to pursue emergency use authorisation to use the drug to treat ARDS.

However, the FDA thwarted Mesoblast’s plan to fast track the authorisation process by requiring the company to complete an additional clinical study to support remestemcel-L’s emergency use authorisation.

This week, Mesoblast announced the FDA has asked it to provide potency assays before the added clinical study begins.

Mesoblast is hoping to get FDA approval to use remestemcel-L to treat SR-aGVHD in children in the future.

The drug has also been used in a controlled study for its potential to treat inflammatory bowel conditions.

FDA negotiations may not be the only weight the Mesoblast share price is battling against.

As The Motley Fool Australia reported on Tuesday, Mesoblast lost US$98.8 million in FY21 and ended the period with just US$136.9 million left in its coffers.

The post Mesoblast (ASX:MSB) shares rise as CEO reassures market on new FDA questions appeared first on The Motley Fool Australia.

Should you invest $1,000 in Mesoblast right now?

Before you consider Mesoblast, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

ASX 200 rises, Harvey Norman falls, Mesoblast sinks

These 3 ASX 200 shares are the most traded this Tuesday

Mesoblast (ASX:MSB) share price crashes 16% to 52-week low on cash concerns
Why Bubs, Harvey Norman, Mesoblast, & Regis shares are dropping

ASX 200 midday update: Harvey Norman’s record profit, PointsBet posts large loss

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!